These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24398500)

  • 1. Reply Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm".
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):77. PubMed ID: 24398500
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: "Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm".
    Giacometti J; Yen MT
    Ophthalmic Plast Reconstr Surg; 2014; 30(1):76-7. PubMed ID: 24398499
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison of preferences between onabotulinumtoxinA (Botox) and incobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm.
    Chundury RV; Couch SM; Holds JB
    Ophthalmic Plast Reconstr Surg; 2013; 29(3):205-7. PubMed ID: 23552607
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A direct comparison of onabotulinumtoxina (Botox) and IncobotulinumtoxinA (Xeomin) in the treatment of benign essential blepharospasm: a split-face technique.
    Saad J; Gourdeau A
    J Neuroophthalmol; 2014 Sep; 34(3):233-6. PubMed ID: 24739994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: a new botulinum neurotoxin A.
    Pagan FL; Harrison A
    Parkinsonism Relat Disord; 2012 Jun; 18(5):441-5. PubMed ID: 22405829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cross-sectional structured survey of patients receiving botulinum toxin type A treatment for blepharospasm.
    Fezza J; Burns J; Woodward J; Truong D; Hedges T; Verma A
    J Neurol Sci; 2016 Aug; 367():56-62. PubMed ID: 27423565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Dosing of OnabotulinumtoxinA and IncobotulinumtoxinA for Cervical Dystonia and Blepharospasm: Results from TRUDOSE and TRUDOSE II.
    Kent R; Robertson A; Quiñones Aguilar S; Tzoulis C; Maltman J
    Toxins (Basel); 2021 Jul; 13(7):. PubMed ID: 34357959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of incobotulinumtoxinA (NT 201, Xeomin) in the treatment of blepharospasm-a randomized trial.
    Jankovic J; Comella C; Hanschmann A; Grafe S
    Mov Disord; 2011 Jul; 26(8):1521-8. PubMed ID: 21520284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated.
    Evidente VG; Truong D; Jankovic J; Comella CL; Grafe S; Hanschmann A
    J Neurol Sci; 2014 Nov; 346(1-2):116-20. PubMed ID: 25186131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blepharospasm with non-satisfactory response to treatment: our experience with IncobotulinumtoxinA.
    Ricciardi L; Ialongo T; Guidubaldi A; Di Giacopo R; Bentivoglio AR
    Parkinsonism Relat Disord; 2014 Jun; 20(6):665-7. PubMed ID: 24685658
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin therapy for apraxia of lid opening.
    Boghen D; Tozlovanu V; Iancu A; Forget R
    Ann N Y Acad Sci; 2002 Apr; 956():482-3. PubMed ID: 11960846
    [No Abstract]   [Full Text] [Related]  

  • 12. Sustained efficacy and safety of repeated incobotulinumtoxinA (Xeomin(®)) injections in blepharospasm.
    Truong DD; Gollomp SM; Jankovic J; LeWitt PA; Marx M; Hanschmann A; Fernandez HH;
    J Neural Transm (Vienna); 2013 Sep; 120(9):1345-53. PubMed ID: 23435927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Electrical activation of the orbicularis oculi muscle does not increase the effectiveness of botulinum toxin type A in patients with blepharospasm.
    Conte A; Fabbrini G; Belvisi D; Marsili L; Di Stasio F; Berardelli A
    Eur J Neurol; 2010 Mar; 17(3):449-55. PubMed ID: 19968711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin in blepharospasm and oromandibular dystonia: comparing different botulinum toxin preparations.
    Bhidayasiri R; Cardoso F; Truong DD
    Eur J Neurol; 2006 Feb; 13 Suppl 1():21-9. PubMed ID: 16417594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year experience with incobotulinumtoxinA (Xeomin(®) ): the first botulinum toxin drug free of complexing proteins.
    Dressler D
    Eur J Neurol; 2012 Mar; 19(3):385-9. PubMed ID: 22035051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switch from abobotulinumtoxinA (Dysport®) to incobotulinumtoxinA (Xeomin®) botulinum toxin formulation: a review of 257 cases.
    Grosset DG; Tyrrell EG; Grosset KA
    J Rehabil Med; 2015 Feb; 47(2):183-6. PubMed ID: 25325305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of high-dose botulinum A toxin in benign essential blepharospasm: is too high too much?
    Pang AL; O'Day J
    Clin Exp Ophthalmol; 2006 Jul; 34(5):441-4. PubMed ID: 16872340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of botulinum toxins for treatment of movement disorders: real-world utilization and cost analysis in a national Medicare population.
    Kazerooni R; Watanabe JH
    J Manag Care Spec Pharm; 2021 Apr; 27(4):478-487. PubMed ID: 33511895
    [No Abstract]   [Full Text] [Related]  

  • 19. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm.
    Ababneh OH; Cetinkaya A; Kulwin DR
    Clin Exp Ophthalmol; 2014 Apr; 42(3):254-61. PubMed ID: 23844601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Injecting botulinum toxin into the treatment of blepharospasm.
    Popescu MN; Popescu SI; Cernat CC; Boariu AM; Călin E; Vieru A; Muşat O
    Rom J Ophthalmol; 2018; 62(2):162-165. PubMed ID: 30206561
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.